Seaport Therapeutics SPTX

NASDAQ SPTX
$19.12 -0.86 (-4.30%)
At close: Nov 16, 2026 · 4:00 PM EST

Seaport Therapeutics (SPTX) stock price is $19.12, down 4.30% on the day, as of Nov 16, 2026. It has a market cap of $1.03Bn, and is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats
Market Cap1.03 Bn
P/E-7.40
FCF (Yr)-77.59 Mn
ROA (Yr)-26.41
EV to EBIT-0.42
Net Income (Yr)-74.88 Mn
Enterprise Value63.31 Mn
Add ratio to table…

About

Seaport Therapeutics, Inc. is a clinical stage therapeutics company focused on inventing and developing new medicines for patients with depression anxiety and other debilitating neuropsychiatric disorders. The company’s core activity is to take clinically validated molecules that suffer from high first pass metabolism low bioavailability or side effects and to apply its proprietary Glyph platform to create lymphatic targeting prodrugs. Glyph is designed to bypass the liver…

Read more ↓
Sector: Healthcare Sector rationale Seaport Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric disorders, such as GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Its core business is the discovery and development of therapeutic prodrugs, which falls squarely within the Pharmaceuticals and Biotechnology industries of the Healthcare sector. Industry: Pharmaceuticals Pharmaceuticals Primary Seaport Therapeutics is a clinical-stage company developing branded prescription medicines for neuropsychiatric disorders, such as GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Its business model focuses on creating new composition of matter intellectual property for branded pharmaceutical sales. Classified using BQ-MICS CIK: 0002042347
Bull & bear

Investment Thesis

▲ Bull case
  • Seaport Therapeutics successfully raised approximately $255 million in its upsized IPO, significantly exceeding its initial target of $212.4 million, which reflects strong investor confidence in the company’s neuropsychiatric pipeline despite the crowded biotech IPO landscape. This capital infusion provides a substantial runway to advance GlyphAllo, its lead oral candidate for major depressive disorder, through later-stage clinical trials without immediate dilution concerns, allowing management to focus on execution rather than financing. The oversubscription suggests that investors are particularly bullish on the oral delivery mechanism for neuropsychiatric indications, which could offer advantages over existing injectable or intravenous therapies in terms of patient adherence and market accessibility. With GlyphAllo targeting a large and underserved patient population suffering from treatment-resistant depression, the company is positioned to capture meaningful share if clinical efficacy and safety profiles meet expectations, especially given the high unmet need and premium pricing potential in this therapeutic area.
  • The timing of Seaport’s IPO coincides with a broader reopening of the U.S. IPO window driven by improving risk appetite and stronger institutional sentiment, creating a favorable environment for biotech valuations that may not be fully reflected in current public market comparables. Unlike many peers that delayed offerings due to volatility, Seaport’s ability to price and upsize its deal indicates that investors are differentiating its science and de-risked clinical stage from more speculative early-stage entrants, suggesting the market may be underestimating the quality of its asset base. Furthermore, the involvement of top-tier underwriters including Goldman Sachs, J.P. Morgan, and Leerink Partners signals institutional endorsement that could support post-IPO liquidity and analyst coverage, reducing the typical volatility seen in newly listed biotechs. This structural tailwind, combined with a clearsighted focus on oral neuropsychiatric therapeutics, may allow Seaport to outperform peers as it progresses toward key clinical milestones.
▼ Bear case
  • Despite the successful IPO, Seaport Therapeutics remains a clinical-stage company with no approved products and significant execution risk, as its lead candidate GlyphAllo is still in development for major depressive disorder with no public disclosure of clinical trial phases or data in the provided news, raising concerns about the maturity of its pipeline and proximity to revenue generation. The company is entering a highly competitive neuropsychiatric market dominated by established players with entrenched therapies and robust intellectual property, where differentiation through oral delivery alone may not suffice without compelling efficacy or safety advantages, especially given the high failure rates in CNS drug development. Without visibility into trial timelines, endpoints, or interim results, investors may be overpaying for future potential that is not yet substantiated by data, making the valuation sensitive to any clinical setbacks or delays that could erode the post-IPO premium.
  • The broader IPO momentum described in the news may be transient, driven by temporary risk appetite rather than fundamental improvements in biotech financing sustainability, meaning Seaport could face renewed funding challenges if market sentiment shifts before it achieves key milestones, particularly if its clinical programs encounter delays or unfavorable outcomes. Additionally, the simultaneous IPOs of Hemab Therapeutics and other companies in overlapping or adjacent sectors suggest increasing competition for investor capital within the biotech space, which could compress valuations and limit follow-on funding options for Seaport if it needs to return to the market sooner than anticipated. The lack of discussion around partnerships, licensing deals, or proprietary platform advantages in the news further implies that the company may be relying solely on internal development, increasing both financial and technical risk as it scales operations without external validation or de-risking through collaboration.
Peer percentiles

How Seaport Therapeutics ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −7.72xMedian 17.0x 64th
  • P/FCFNegative free cash flow −11.3xMedian 19.0x 67th
  • P/Operating cash flowNegative operating cash flow −11.2xMedian 16.4x 66th
  • P/S 90.6xMedian 8.38x 18th
  • P/B 2.69xMedian 2.04x 42nd
  • P/Tangible book 2.69xMedian 2.31x 44th
  • EV/EBITDANegative EBITDA −5.13xMedian 14.6x 52nd
  • EV/EBITNegative EBIT −5.16xMedian 18.4x 54th
  • EV/Revenue 66.0xMedian 6.34x 18th
  • EV/FCFNegative free cash flow −8.20xMedian 23.4x 57th
  • EV/Operating cash flowNegative operating cash flow −8.15xMedian 19.3x 57th
  • PEG (3Y EPS CAGR) —Median 0.43 No data —
Peer group

Peer Comparison

Companies in the Pharmaceuticals
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,276.89 Bn46.3014.7749.50 Bn
2 JNJ Johnson & Johnson 681.31 Bn42.336.8644.65 Bn
3 ABBV AbbVie Inc. 520.63 Bn50.347.8980.90 Bn
4 MRK Merck & Co., Inc. 357.22 Bn145.635.3053.78 Bn
5 NVS Novartis Ag 310.90 Bn17.915.08-
6 AZN Astrazeneca Plc 285.12 Bn25.854.80-5.53 Bn
7 AMGN Amgen Inc 250.23 Bn26.656.4354.01 Bn
8 SPTX Seaport Therapeutics, Inc. 1.03 Bn-7.4086.84-